F-1: Kazia Therapeutics Files for Resale of 4.7 Million ADSs Following Private Placement

Kazia Therapeutics seeks to register the resale of American Depositary Shares (ADSs) issued in connection with recent private placements.

Summary

• Kazia Therapeutics has filed a registration statement for the resale of up to 4,755,556 American Depositary Shares (ADSs).
• These ADSs represent 47,555,560 ordinary shares issued or issuable upon the exercise of warrants from a concurrent private placement related to a registered direct offering in December 2023 and warrants issued to the placement agent, H.C. Wainwright & Co., LLC.
• The company will not receive any proceeds from the sale of these ADSs by the selling shareholders.
• The ADSs are listed on the Nasdaq Capital Market under the symbol KZIA, with the last reported sale price on January 29, 2024, at $0.3385 per ADS.
• Kazia Therapeutics is a foreign private issuer and is subject to reduced public company reporting requirements.

Sentiment

Score: 5

Explanation: Neutral sentiment. The document is a regulatory filing related to a planned resale of securities. It does not contain overtly positive or negative information about the company's operations or prospects.

Risks

• The market price of the ADSs has been and will likely continue to be volatile and you could lose all or part of your investment.
• If we cannot meet Nasdaqs continued listing requirements, Nasdaq may delist the ADSs, which could have an adverse impact on the liquidity and market price of the ADSs.
• Raising additional capital may cause dilution to our existing shareholders, restrict our operations or cause us to relinquish valuable rights.
• Future sales or issuances of the ADSs in the public markets, or the perception of such sales, could depress the trading price of the ADSs.
• You are reliant on the Depositary to exercise your voting rights and to receive distributions on ADSs and, as a result, you may be unable to exercise your voting rights on a timely basis or you may not receive certain distributions.
• We do not currently intend to pay dividends on our securities and, consequently, your ability to achieve a return on your investment will depend on appreciation in the price of the ADSs.

Future Outlook

The company intends to use the proceeds from the exercise of the Warrants for cash, if any, for general corporate purposes, which may include working capital, expenses related to research, clinical development and commercial efforts, and general and administrative expenses.

Industry Context

Kazia Therapeutics is an oncology-focused biotechnology company, and this announcement is related to its financing activities to support the development of its drug candidates.

Stakeholder Impact

• Existing shareholders may experience dilution if the warrants are exercised and the ADSs are sold.
• The resale of ADSs could affect the market price of the stock.
• The company's ability to fund its operations depends on its access to capital.

Next Steps

• The selling shareholders may offer or resell the Offered ADSs from time to time pursuant to this prospectus.
• Kazia Therapeutics intends to monitor the bid price of the ADSs and will consider taking such actions as may be necessary and appropriate to achieve compliance with continued listing requirements prior to the expiration of all available grace periods.

Key Dates

Keywords

ADSs, Kazia Therapeutics, resale, warrants, private placement, ordinary shares, registration statement, securities